Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 vs Aflibercept in wAMD (DAYLIGHT)
NCT04964089Phase 3Completed
- Sponsor
- Kodiak Sciences
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of tarcocimab tedromer in neovascular age-related macular degeneration (NVAMD), sponsored by Kodiak Sciences. Started Jun 2021; status: completed.
02
Drugs
tarcocimab tedromer
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04964089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964089.